Marko Stoiljkovic

Dr. Marko Stoiljkovic

Department of Internal Medicine, Medical center Sveti Luka, Smederevo, Serbia
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MSMarko Stoiljkovic
Marko Stoiljkovic
Vladimir JakovljevicVladimir Jakovljevic
Vladimir Jakovljevic
JMJovan Milosavljevic
Jovan Milosavljevic
SBSergey Bolevich
Sergey Bolevich
NJNevena Jeremic
Nevena Jeremic
VZVladimir Zivkovic
Vladimir Zivkovic
Captopril, a well-established angiotensin-converting enzyme (ACE) inhibitor, has garnered attention for its cardioprotective effects in preventing heart remodeling and maintaining cardiac function, significantly improving life quality. However, recent studies have revealed that in addition to known hemodynamic alterations, captopril exhibits significant antioxidant, anti-inflammatory, and immunomodulatory effects that may underlie its protective mechanisms. Although it appeared to be overlooked in clinical practice, in recent years, additional efforts have been made to uncover the mechanisms of all drug effects, as recent research studies predict a wide spectrum of diseases beyond the recommended indications. This review thoroughly examines the mechanisms by which captopril mediates its protective effects, bridging basic biochemical observations with applied clinical investigation, especially during ischemic reperfusion (I/R) injury, hypertension, and heart failure (HF). Evidence points to captopril as a promising agent for modulating oxidative and inflammatory pathways that are crucial for cardiovascular medicine. Directions for future research are defined to determine the molecular targets of captopril further and to optimize its clinical utility in the management of cardiovascular and possibly other diseases.

21 July 2026 in Journal of the Renin-Angiotensin-Aldosterone System
Verified
Journal Article
Closed access
MSMarko Stoiljkovic
Marko Stoiljkovic
VJVladimir Jakovljevic
Vladimir Jakovljevic
MSMilos Stojiljkovic
Milos Stojiljkovic
SBSergey Bolevich
Sergey Bolevich
DMDusan Mustur
Dusan Mustur
VZVladimir Zivkovic
Vladimir Zivkovic
Introduction Angiotensin-(1-7) (Ang-(1-7)) is a central bioactive component of the renin-angiotensin system (RAS) that counter-regulates angiotensin II signaling via the Mas receptor, thereby maintaining cardiovascular and immune homeostasis. Beyond its vasoprotective effects, the Ang-(1-7)/Mas axis has been increasingly recognized as an important immunomodulatory pathway influencing macrophage biology and vascular inflammation. Methods This narrative review was based on a comprehensive evaluation of experimental, translational, and clinical evidence addressing the role of the Ang-(1-7)/Mas axis in macrophage-mediated vascular inflammation. The literature was critically appraised with emphasis on macrophage phenotype modulation, inflammatory signaling, vascular remodeling, and the therapeutic potential of targeting this protective RAS pathway. Results Ang-(1-7)/Mas signaling suppresses pro-inflammatory macrophage activation, promotes reparative phenotypes, enhances efferocytic and phagocytic functions, and facilitates resolution of inflammation. At the vascular level, this pathway reduces macrophage infiltration, leukocyte recruitment, and endothelial activation, contributing to plaque stabilization and attenuation of adverse remodeling. Emerging evidence highlights receptor cross-talk within the RAS network and context-dependent effects shaped by lesion stage and systemic milieu. Conclusions The Ang-(1-7)/Mas axis represents a promising translational target linking vascular immunobiology with novel therapeutic strategies for macrophage-driven cardiovascular disease. Further experimental and clinical studies are warranted to define its potential across diverse vascular inflammatory settings.